These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21443808)

  • 1. Exposure to depleted uranium does not alter the co-expression of HER-2/neu and p53 in breast cancer patients.
    Al-Mumen MM; Al-Janabi AA; Jumaa AS; Al-Toriahi KM; Yasseen AA
    BMC Res Notes; 2011 Mar; 4():87. PubMed ID: 21443808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of HER-2/neu overexpression in female breast cancer among an Iraqi population exposed to depleted uranium.
    Al-Dujaily EA; Al-Janabi AA; Pierscionek T; Yasseen AA
    J Carcinog; 2008; 7():8. PubMed ID: 19008567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.
    Xu R; Feiner H; Li P; Yee H; Inghirami G; Delgado Y; Perle MA
    Arch Pathol Lab Med; 2003 Nov; 127(11):1458-64. PubMed ID: 14567723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
    Maru D; Middleton LP; Wang S; Valero V; Sahin A
    Cancer; 2005 Mar; 103(5):900-5. PubMed ID: 15643600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer.
    Rosenthal SI; Depowski PL; Sheehan CE; Ross JS
    Appl Immunohistochem Mol Morphol; 2002 Mar; 10(1):40-6. PubMed ID: 11893034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical detection of Her-2/neu overexpression in breast carcinoma in Nigerians: a 5-year retrospective study.
    Ugiagbe EE; Olu-Eddo AN; Obaseki DE
    Niger J Clin Pract; 2011; 14(3):332-7. PubMed ID: 22037080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D.
    Korkolis D; Ardavanis A; Yotis J; Kyroudi A; Gorgoulis V; Kittas C
    Anticancer Res; 2001; 21(3C):2207-12. PubMed ID: 11501848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.
    Ismail MF; Aly MS; Khaled HM; Mohamed HM
    Ger Med Sci; 2009 May; 7():Doc03. PubMed ID: 19675743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of VEGF in urinary bladder transitional cell carcinoma in an Iraqi population subjected to depleted uranium: an immunohistochemical study.
    Al-Abbasi DS; Al-Janabi AA; Al-Toriahi KM; Jabor TA; Yasseen AA
    Appl Immunohistochem Mol Morphol; 2009 Jul; 17(4):307-11. PubMed ID: 19151604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment.
    Climent MA; Seguí MA; Peiró G; Molina R; Lerma E; Ojeda B; López-López JJ; Alonso C
    Breast; 2001 Feb; 10(1):67-77. PubMed ID: 14965564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients.
    Al-Moundhri MS; Nirmala V; Al-Hadabi I; Al-Mawaly K; Burney I; Al-Nabhani M; Thomas V; Ganguly SS; Grant C
    J Surg Oncol; 2005 Sep; 91(4):243-52. PubMed ID: 16121348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
    Rosen PP; Lesser ML; Arroyo CD; Cranor M; Borgen P; Norton L
    J Clin Oncol; 1995 Apr; 13(4):821-30. PubMed ID: 7707107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.
    Sawaki M; Ito Y; Akiyama F; Tokudome N; Horii R; Mizunuma N; Takahashi S; Horikoshi N; Imai T; Nakao A; Kasumi F; Sakamoto G; Hatake K
    Breast Cancer; 2006; 13(2):172-8. PubMed ID: 16755113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan.
    Tsai YS; Tzai TS; Chow NH; Yang WH; Tong YC; Lin JS; Chang CC; Cheng HL; Lin YM
    Urol Int; 2003; 71(3):262-70. PubMed ID: 14512646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study.
    Çiriş IM; Bozkurt KK; Başpinar S; Kapucuoğlu FN
    Pathol Res Pract; 2011 Mar; 207(3):182-7. PubMed ID: 21371829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer.
    Marks JR; Humphrey PA; Wu K; Berry D; Bandarenko N; Kerns BJ; Iglehart JD
    Ann Surg; 1994 Apr; 219(4):332-41. PubMed ID: 7909221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression.
    Lee JS; Kim HS; Jung JJ; Kim YB; Lee MC; Park CS
    Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):289-95. PubMed ID: 12607595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology.
    Ho GH; Calvano JE; Bisogna M; Borgen PI; Rosen PP; Tan LK; Van Zee KJ
    Cancer; 2000 Dec; 89(11):2153-60. PubMed ID: 11147584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Hydrochloric Acid Decalcification on Expression Pattern of Prognostic Markers in Invasive Breast Carcinomas.
    Maclary SC; Mohanty SK; Bose S; Chung F; Balzer BL
    Appl Immunohistochem Mol Morphol; 2017 Feb; 25(2):144-149. PubMed ID: 27028239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.